Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
IPO Year:
Exchange: NASDAQ
Website: utahmed.com
10-Q - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
8-K - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
SCHEDULE 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SD - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
10-Q - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
8-K - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
8-K - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
DEF 14A - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
10-K - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
8-K - UTAH MEDICAL PRODUCTS INC (0000706698) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
4 - UTAH MEDICAL PRODUCTS INC (0000706698) (Issuer)
Fastest customizable press release news feed in the world
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S. in Communications from Santa Clara University and an MBA from the Northwestern University Kellogg School of Management. As she served in her last position as UTMD's manager of Global Direct End User Sales, the Board believes her robust understanding of the functional and strategic challenges that the Company faces will be integral for achieving future revenue growth.In addition, the Board of Directors appr
SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections.Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted.Overview of ResultsThe following is a summary comparison of 3Q and 9M of calendar 2024 with 3Q and 9M 2023 income statement mea
SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtain
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (NASDAQ:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues.Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results
SALT LAKE CITY, UT / ACCESSWIRE / May 7, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on July 5, 2024 to stockholders of record at the close of business on June 14, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal
SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024.Summary of results .The following is a summary comparison of 1Q 2024 with 1Q 2023 income statement measures:Revenues (Sales): -9.40%Gross Profit (GP): -13.70%Operating Income (OI): -12.50%Net Income (NI): -6.10%Earnings Per Share (EPS): -5.70% Profit margins in 1Q 2024 compared to 1Q 2023 follow: 1Q 2024 1Q 2023 (JAN - MAR) (JAN - MAR) Gross Profit Margin (gross profits/ sales): 59.70% 62.60%Operating Income Margin (operating income/ sales): 34
SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (NASDAQ:UTMD) achieved financial results for the full year of 2023 consistent with management's beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Overview of Results A summary comparison of 4Q and calendar year 2023 income statement measures with the sam
SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023. This is a 1.7% increase over the prior regular quarterly cash dividend.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long
SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. (NASDAQ:UTMD), despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Overview of Results The following is a summary comparison of 3Q and first nine months (9M) of calendar 2023 with 3Q and 9M 2022 inc
SALT LAKE CITY, UT / ACCESSWIRE / August 31, 2023 / As Utah Medical Products, Inc.'s (NASDAQ:UTMD) stockholders know, the following disclosure was included in the Company's 2022 SEC 10-K annual report, released in March 2023:"In late 2021, after the Filshie clip had been used in the U.S. for 25 years and implanted in millions of women, a clip migration lawsuit was filed in Texas. Subsequently, the same law firm solicited and recruited claimants in other states. As of the end of January 2023, there were a total of fourteen clip migration lawsuits initiated by the same law firm in twelve different states. UTMD has filed motions to dismiss in most of those lawsuits, one of which has been grante
Live Leadership Updates
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S. in Communications from Santa Clara University and an MBA from the Northwestern University Kellogg School of Management. As she served in her last position as UTMD's manager of Global Direct End User Sales, the Board believes her robust understanding of the functional and strategic challenges that the Company faces will be integral for achieving future revenue growth.In addition, the Board of Directors appr
This live feed shows all institutional transactions in real time.
Live finance-specific insights
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SC 13G/A - UTAH MEDICAL PRODUCTS INC (0000706698) (Subject)
SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections.Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted.Overview of ResultsThe following is a summary comparison of 3Q and 9M of calendar 2024 with 3Q and 9M 2023 income statement mea
SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtain
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (NASDAQ:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues.Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results
SALT LAKE CITY, UT / ACCESSWIRE / May 7, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on July 5, 2024 to stockholders of record at the close of business on June 14, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal
SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024.Summary of results .The following is a summary comparison of 1Q 2024 with 1Q 2023 income statement measures:Revenues (Sales): -9.40%Gross Profit (GP): -13.70%Operating Income (OI): -12.50%Net Income (NI): -6.10%Earnings Per Share (EPS): -5.70% Profit margins in 1Q 2024 compared to 1Q 2023 follow: 1Q 2024 1Q 2023 (JAN - MAR) (JAN - MAR) Gross Profit Margin (gross profits/ sales): 59.70% 62.60%Operating Income Margin (operating income/ sales): 34
SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (NASDAQ:UTMD) achieved financial results for the full year of 2023 consistent with management's beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Overview of Results A summary comparison of 4Q and calendar year 2023 income statement measures with the sam
SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023. This is a 1.7% increase over the prior regular quarterly cash dividend.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long
SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. (NASDAQ:UTMD), despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Overview of Results The following is a summary comparison of 3Q and first nine months (9M) of calendar 2023 with 3Q and 9M 2022 inc
SALT LAKE CITY, UT / ACCESSWIRE / August 1, 2023 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on October 3, 2023 to shareholders of record at the close of business on September 15, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the
SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. (NASDAQ:UTMD) achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicati